秋水仙碱可降低 COVID-19 患者中 NLRP3 炎症小体的激活。
Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients.
机构信息
Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, 14.048-900, São Paulo, Brazil.
Department of Cell Biology, University of São Paulo, Ribeirao Preto, São Paulo, Brazil.
出版信息
Inflamm Res. 2023 May;72(5):895-899. doi: 10.1007/s00011-023-01718-y. Epub 2023 Mar 14.
OBJECTIVE
To evaluate whether colchicine treatment was associated with the inhibition of NLRP3 inflammasome activation in patients with COVID-19.
METHODS
We present a post hoc analysis from a double-blinded placebo-controlled randomized clinical trial (RCT) on the effect of colchicine for the treatment of COVID-19. Serum levels of NOD-like receptor protein 3 (NLRP3) inflammasome products-active caspase-1 (Casp1p20), IL-1β, and IL-18-were assessed at enrollment and after 48-72 h of treatment in patients receiving standard-of-care (SOC) plus placebo vs. those receiving SOC plus colchicine. The colchicine regimen was 0.5 mg tid for 5 days, followed by 0.5 mg bid for another 5 days.
RESULTS
Thirty-six patients received SOC plus colchicine, and thirty-six received SOC plus placebo. Colchicine reduced the need for supplemental oxygen and the length of hospitalization. On Days 2-3, colchicine lowered the serum levels of Casp1p20 and IL-18, but not IL-1β.
CONCLUSION
Treatment with colchicine inhibited the activation of the NLRP3 inflammasome, an event triggering the 'cytokine storm' in COVID-19.
TRIAL REGISTRATION NUMBERS
RBR-8jyhxh.
目的
评估秋水仙碱治疗是否与抑制 COVID-19 患者 NLRP3 炎性体激活有关。
方法
我们对秋水仙碱治疗 COVID-19 的双盲安慰剂对照随机临床试验（RCT）进行了事后分析。在接受标准治疗（SOC）加安慰剂与接受 SOC 加秋水仙碱的患者中，在入组时和治疗后 48-72 小时评估 NOD 样受体蛋白 3（NLRP3）炎性体产物-活性半胱天冬酶-1（Casp1p20）、IL-1β和 IL-18 的血清水平。秋水仙碱方案为每天 tid 0.5mg，连用 5 天，然后每天 bid 0.5mg，再连用 5 天。
结果
36 例患者接受 SOC 加秋水仙碱治疗，36 例患者接受 SOC 加安慰剂治疗。秋水仙碱降低了补充氧气的需求和住院时间。在第 2-3 天，秋水仙碱降低了 Casp1p20 和 IL-18 的血清水平，但没有降低 IL-1β。
结论
秋水仙碱治疗抑制了 NLRP3 炎性体的激活，这是 COVID-19 中“细胞因子风暴”的触发因素。
试验注册号
RBR-8jyhxh。
Zotero 插件